AnaptysBio to Spin Off Biopharma Portfolio

Dow Jones

Mar 04

By Katherine Hamilton

AnaptysBio is spinning off its biopharmaceutical operations into a separate public company as soon as late April.

The clinical-stage biotechnology company said Tuesday it plans to separate the biopharma portfolio from its royalty assets during the second quarter of 2026.

The royalty management company will initially retain the name AnaptysBio, as well as the ticker ANAB on the Nasdaq, and will manage the financial collaborations from Jemperli with GSK and imsidolimab with Vanda.

Daniel Faga is anticipated to be the initial chief executive of the royalty management company, though specific decisions about the board composition and leadership will be disclosed later, AnaptysBio said.

The spinoff will be called First Tracks Biotherapeutics, and will trade under the ticker TRAX on the Nasdaq. It will focus on the development and potential commercialization of immunology treatments.

Faga will also be chief executive of First Tracks Biotherapeutics to start.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 03, 2026 17:08 ET (22:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616342377"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616342377\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616342377?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 06:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616342377","market":"nz","top_or_hot":-1,"title":"AnaptysBio to Spin Off Biopharma Portfolio","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AnaptysBio is spinning off its biopharmaceutical operations into a separate public company as soon as late April. \n</p>\n<p>\n  The clinical-stage biotechnology company said Tuesday it plans to separate the biopharma portfolio from its royalty assets during the second quarter of 2026. \n</p>\n<p>\n  The royalty management company will initially retain the name AnaptysBio, as well as the ticker ANAB on the Nasdaq, and will manage the financial collaborations from Jemperli with GSK and imsidolimab with Vanda. \n</p>\n<p>\n  Daniel Faga is anticipated to be the initial chief executive of the royalty management company, though specific decisions about the board composition and leadership will be disclosed later, AnaptysBio said. \n</p>\n<p>\n  The spinoff will be called First Tracks Biotherapeutics, and will trade under the ticker TRAX on the Nasdaq. It will focus on the development and potential commercialization of immunology treatments. \n</p>\n<p>\n  Faga will also be chief executive of First Tracks Biotherapeutics to start. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2026 17:08 ET (22:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AnaptysBio to Spin Off Biopharma Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnaptysBio to Spin Off Biopharma Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-04 06:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  AnaptysBio is spinning off its biopharmaceutical operations into a separate public company as soon as late April. \n</p>\n<p>\n  The clinical-stage biotechnology company said Tuesday it plans to separate the biopharma portfolio from its royalty assets during the second quarter of 2026. \n</p>\n<p>\n  The royalty management company will initially retain the name AnaptysBio, as well as the ticker ANAB on the Nasdaq, and will manage the financial collaborations from Jemperli with GSK and imsidolimab with Vanda. \n</p>\n<p>\n  Daniel Faga is anticipated to be the initial chief executive of the royalty management company, though specific decisions about the board composition and leadership will be disclosed later, AnaptysBio said. \n</p>\n<p>\n  The spinoff will be called First Tracks Biotherapeutics, and will trade under the ticker TRAX on the Nasdaq. It will focus on the development and potential commercialization of immunology treatments. \n</p>\n<p>\n  Faga will also be chief executive of First Tracks Biotherapeutics to start. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2026 17:08 ET (22:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616342377","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616342377","pubTimestamp":1772575680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AnaptysBio is spinning off its biopharmaceutical operations into a separate public company as soon as late April.The clinical-stage biotechnology company said Tuesday it plans to separate the biopharma portfolio from its royalty assets during the second quarter of 2026.The royalty management company will initially retain the name AnaptysBio, as well as the ticker ANAB on the Nasdaq, and will manage the financial collaborations from Jemperli with GSK and imsidolimab with Vanda.Daniel Faga is anticipated to be the initial chief executive of the royalty management company, though specific decisions about the board composition and leadership will be disclosed later, AnaptysBio said.The spinoff will be called First Tracks Biotherapeutics, and will trade under the ticker TRAX on the Nasdaq. It will focus on the development and potential commercialization of immunology treatments.Faga will also be chief executive of First Tracks Biotherapeutics to start.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ANAB":"Anaptysbio Inc"},"translate_title":"AnaptysBio将剥离生物制药产品组合","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  AnaptysBio is spinning off its biopharmaceutical operations into a separate public company as soon as late April. \n\n\n  The clinical-stage biotechnology company said Tuesday it plans to separate the biopharma portfolio from its royalty assets during the second quarter of 2026. \n\n\n  The royalty management company will initially retain the name AnaptysBio, as well as the ticker ANAB on the Nasdaq, and will manage the financial collaborations from Jemperli with GSK and imsidolimab with Vanda. \n\n\n  Daniel Faga is anticipated to be the initial chief executive of the royalty management company, though specific decisions about the board composition and leadership will be disclosed later, AnaptysBio said. \n\n\n  The spinoff will be called First Tracks Biotherapeutics, and will trade under the ticker TRAX on the Nasdaq. It will focus on the development and potential commercialization of immunology treatments. \n\n\n  Faga will also be chief executive of First Tracks Biotherapeutics to start. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 17:08 ET (22:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}